Related Experiment Video
Updated: Jul 13, 2026
06:57
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis
Arne Egesten1, Mette Eliasson, Anders I Olin
1Department of Clinical Sciences Lund, BMC B14, Tornavagen 10, 221 84, Lund, Sweden. Arne.Egesten@med.lu.se
International Journal of Colorectal Disease
|August 19, 2007
Summary
Chemokines like growth-related oncogene-alpha (GRO-alpha) are elevated in ulcerative colitis and may indicate disease activity. Corticosteroid treatment reduced these inflammatory markers, suggesting potential new therapeutic targets.
Area of Science:
- Gastroenterology
- Immunology
- Molecular Biology
Background:
- Ulcerative colitis involves mucosal inflammation with granulocytes, T cells, and NK cells.
- Chemokines regulate inflammation; CXC-chemokines like GRO-alpha/CXCL1, IL-8/CXCL8, MIG/CXCL9, CXCL10, and CXCL11 play distinct roles in immune cell recruitment and activation.
Purpose of the Study:
- To investigate the expression of CXC-chemokines in ulcerative colitis patients.
- To assess the impact of corticosteroid treatment on CXC-chemokine levels.
- To explore the potential of CXC-chemokines as therapeutic targets and disease markers.
Main Methods:
- Studied CXC-chemokine expression in 11 ulcerative colitis patients and 8 controls.
- Collected colon perfusates and biopsies before and during corticosteroid treatment.
- Measured GRO-alpha and MIG levels using ELISA and detected tissue expression via immunohistochemistry.
Main Results:
- Elevated levels of GRO-alpha, IL-8, and MIG were found in ulcerative colitis patients compared to controls.
- Corticosteroid treatment led to decreased GRO-alpha and MIG levels.
- Sustained high levels of GRO-alpha and MIG were observed in non-responders.
- GRO-alpha and MIG were expressed by epithelial cells and granulocytes in the colonic submucosa.
Conclusions:
- CXC-chemokines are implicated in ulcerative colitis pathophysiology.
- These chemokines represent potential targets for novel ulcerative colitis treatments.
- GRO-alpha may serve as a valuable marker for assessing ulcerative colitis disease activity.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...